Rt-PA causes a significant increase in endogenous u-PA during experimental focal cerebral ischemia

Eur J Neurosci. 2004 Dec;20(11):2903-8. doi: 10.1111/j.1460-9568.2004.03757.x.

Abstract

The aim of this study was to investigate the effects of different doses of exogenous recombinant human tissue plasminogen activator (rt-PA) on the endogenous cerebral plasminogen-plasmin system in focal ischemia in rats. Ischemia was induced using the suture model. Each group of rats (n = 6) received either treatment (0.9, 9 or 18 mg rt-PA/kg body weight) or saline (control group) at the end of ischemia; a sham-operated group was added. The activity of the plasminogen activators was measured by casein-dependent plasminogen zymography. In the cortex urokinase (u-PA) rose from sham (no ischemia), 91 +/- 7% to ischemia, 176 +/- 10% (P < 0.005). Increasing rt-PA doses led to further significant (P < 0.001) cortical u-PA activation which was maximal at 18 mg: 249 +/- 13%. An extreme increase in the u-PA activity was observed in the basal ganglia to 1019 +/- 22% (P < 0.001). This increase was further aggravated by higher rt-PA doses (18 mg, 1236 +/- 15%; P < 0.001). The t-PA level did not change I3R24 during (3 h ischemia followed by reperfusion for 24 h); however, during low and moderate doses of rt-PA, endogenous t-PA was reduced. In conclusion, while ischemia leads to a significant increase in u-PA, mainly in the basal ganglia, t-PA is not altered. Increasing doses of rt-PA lead to a further elevation of u-PA. Thus, u-PA seems to play a major role in the endogenous plasminogen activator system following focal cerebral ischemia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Basal Ganglia / drug effects
  • Basal Ganglia / enzymology
  • Blotting, Western / methods
  • Brain Ischemia / enzymology*
  • Caseins / pharmacology
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / enzymology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Activation / drug effects
  • Humans
  • Male
  • Plasminogen / pharmacology
  • Rats
  • Rats, Wistar
  • Recombinant Proteins / administration & dosage
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / pharmacology*
  • Urokinase-Type Plasminogen Activator / metabolism*
  • Urokinase-Type Plasminogen Activator / pharmacology

Substances

  • Caseins
  • Recombinant Proteins
  • Plasminogen
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator